ATE168013T1 - Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung - Google Patents

Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung

Info

Publication number
ATE168013T1
ATE168013T1 AT91909612T AT91909612T ATE168013T1 AT E168013 T1 ATE168013 T1 AT E168013T1 AT 91909612 T AT91909612 T AT 91909612T AT 91909612 T AT91909612 T AT 91909612T AT E168013 T1 ATE168013 T1 AT E168013T1
Authority
AT
Austria
Prior art keywords
antibodies
icam
humanized
infection
production method
Prior art date
Application number
AT91909612T
Other languages
English (en)
Inventor
John Robert George Adair
Martyn Kim Robinson
Susan Margaret Bright
Robert A Rothlein
Original Assignee
Celltech Therapeutics Ltd
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd, Boehringer Ingelheim Pharma filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE168013T1 publication Critical patent/ATE168013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91909612T 1990-04-27 1991-04-29 Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung ATE168013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009548A GB9009548D0 (en) 1990-04-27 1990-04-27 Chimeric antibody and method

Publications (1)

Publication Number Publication Date
ATE168013T1 true ATE168013T1 (de) 1998-07-15

Family

ID=10675133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909612T ATE168013T1 (de) 1990-04-27 1991-04-29 Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung

Country Status (14)

Country Link
EP (1) EP0528931B1 (de)
JP (1) JPH05507406A (de)
AT (1) ATE168013T1 (de)
AU (1) AU649682B2 (de)
BR (1) BR9106394A (de)
CA (1) CA2081479A1 (de)
DE (1) DE69129743T2 (de)
DK (1) DK0528931T3 (de)
ES (1) ES2118084T3 (de)
FI (1) FI924819L (de)
GB (1) GB9009548D0 (de)
HU (1) HUT66103A (de)
NO (2) NO924088L (de)
WO (1) WO1991016928A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0362531B1 (de) 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
EP0578819A4 (de) * 1992-01-27 1994-10-12 Icos Corp Icam ähnliche proteine.
US5700658A (en) * 1992-01-27 1997-12-23 Icos Corporation ICAM-4 materials and methods
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
US5773293A (en) * 1992-01-27 1998-06-30 Icos Corporation Anti-ICAM-4 antibodies and hybridomas
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5852170A (en) * 1992-01-27 1998-12-22 Icos Corporation ICAM-4 materials and methods
US5753502A (en) * 1993-08-05 1998-05-19 Icos Corporation Neuron-specific ICAM-4 promoter
EP0628057B1 (de) * 1992-02-28 1999-10-20 Board Of Regents The University Of Texas System Verwendung einer therapeutischen ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON VERBRENNUNGEN
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
AU6390696A (en) * 1995-06-20 1997-01-22 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
KR100847441B1 (ko) 1996-09-26 2008-07-21 츄가이 세이야꾸 가부시키가이샤 인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP2363484A3 (de) 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanisierter Antikörper gegen den menschlichen Gewebefaktor (TF) und Verfahren zur Herstellung des humanisierten Antikörpers
EP1102601B1 (de) * 1998-08-04 2005-11-23 The Trustees Of The University Of Pennsylvania Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
ATE439145T1 (de) 1999-03-19 2009-08-15 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
ATE429518T1 (de) 1999-06-24 2009-05-15 Univ Johns Hopkins Zusammensetzungen und methoden zur vorbeugung transepithelialer übertragung von hiv
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US7674466B2 (en) 1999-08-05 2010-03-09 The Trustees Of The University Of Pennsylvania Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
DK1283214T3 (da) 2000-04-21 2007-06-11 Fuso Pharmaceutical Ind Hidtil ukendte kollektiner
US8029793B2 (en) 2000-04-28 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for inhibiting cell proliferation
KR20030055274A (ko) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 저분자화 트롬보포에틴 아고니스트 항체
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2532027C (en) 2003-07-18 2016-06-14 Amgen Inc. Specific binding agents to hepatocyte growth factor
ES2484340T3 (es) * 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
WO2005123777A2 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
EP1870458B1 (de) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2655289C (en) 2006-06-21 2016-08-23 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8026343B2 (en) 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
EP2351777B1 (de) 2008-10-28 2015-10-28 Shionogi&Co., Ltd. Anti-muc1-antikörper
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2011081904A1 (en) 2009-12-14 2011-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
KR101434029B1 (ko) * 2012-09-14 2014-08-26 서울대학교산학협력단 Ｉｃａｍ－1에 대한 항체 및 그 용도
EP4285988A3 (de) 2013-03-27 2024-03-06 Cedars-Sinai Medical Center Behandlung von fibrose durch tl1a-hemmung
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
WO2018170398A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP4703381A1 (de) * 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antikörper gegen icam-1 und anwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
WO1990013316A1 (en) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination of hiv-1 infected cells
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method

Also Published As

Publication number Publication date
ES2118084T3 (es) 1998-09-16
DE69129743D1 (de) 1998-08-13
DK0528931T3 (da) 1999-04-19
NO924088D0 (no) 1992-10-22
GB9009548D0 (en) 1990-06-20
FI924819A0 (fi) 1992-10-23
AU7860391A (en) 1991-11-27
NO924088L (no) 1992-12-23
HU9203370D0 (en) 1993-01-28
BR9106394A (pt) 1993-04-27
EP0528931A1 (de) 1993-03-03
EP0528931A4 (en) 1993-04-28
CA2081479A1 (en) 1991-10-28
JPH05507406A (ja) 1993-10-28
AU649682B2 (en) 1994-06-02
NO984136L (no) 1992-12-23
WO1991016928A1 (en) 1991-11-14
DE69129743T2 (de) 1999-02-11
EP0528931B1 (de) 1998-07-08
FI924819A7 (fi) 1992-10-23
FI924819L (fi) 1992-10-23
NO984136D0 (no) 1998-09-08
HUT66103A (en) 1994-09-28

Similar Documents

Publication Publication Date Title
ATE168013T1 (de) Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
EP1245676A4 (de) Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
ATE403680T1 (de) Herstellung tetravalenter antikörper
DE69941598D1 (de) Anti-ccr2 antikörper sowie deren verwendung
LU93274I2 (fr) Elotuzumab
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DK1265928T3 (da) RSV-neutraliserende antistoffer med ultra høj affinitet
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
EP1106183A3 (de) Antikörper gegen ErbB2 und deren therapeutische Verwendungen
EP0724651A4 (de) Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
TR200102493T2 (tr) IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
DE69128543D1 (de) Monoklonale antikörper der maus
SE8700467D0 (sv) Cross-protective human monoclonal antibody compositions
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee